{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:11:08Z","timestamp":1790799068859,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajo.2024.12.009","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:18:59Z","timestamp":1734434339000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["High Body Mass Index is Associated with Lower Adalimumab Serum Levels and Higher Disease Activity in Noninfectious Uveitis"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-4166","authenticated-orcid":false,"given":"Francesco","family":"Pichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar H","family":"AlAli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6206-3483","authenticated-orcid":false,"given":"Yanny Perez","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7673-4276","authenticated-orcid":false,"given":"Piergiorgio","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2024.12.009_bib0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","article-title":"A focus on the epidemiology of uveitis","volume":"26","author":"Tsirouki","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"1106","key":"10.1016\/j.ajo.2024.12.009_bib0002","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/postgradmedj-2017-134891","article-title":"Uveitis: a sight-threatening disease which can impact all systems","volume":"93","author":"Krishna","year":"2017","journal-title":"Postgrad Med J"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/09273948.2013.874445","article-title":"Quality of life in patients with noninfectious uveitis treated with or without systemic anti-inflammatory therapy","volume":"23","author":"Gui","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.009_bib0004","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ophtha.2010.03.029","article-title":"A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States","volume":"118","author":"Nguyen","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.12.009_bib0005","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2147\/DDDT.S160431","article-title":"Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review","volume":"12","author":"Ming","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.009_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2015.07.001","article-title":"The ocular immunology and uveitis foundation preferred practice patterns of uveitis management","volume":"61","author":"Foster","year":"2016","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.009_bib0007","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitiS (FOCUS) initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.009_bib0008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/09273948.2010.531176","article-title":"TNF inhibitors for uveitis: balancing efficacy and safety","volume":"18","author":"Cunningham","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.009_bib0009","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/25785826.2019.1642080","article-title":"The effectiveness of adalimumab treatment for non-infectious uveitis","volume":"42","author":"Hasegawa","year":"2019","journal-title":"Immunol Med"},{"key":"10.1016\/j.ajo.2024.12.009_bib0011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ajo.2023.09.012","article-title":"The humira in ocular inflammations taper (HOT) study","volume":"258","author":"Pichi","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.009_bib0012","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1623847","article-title":"Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study","volume":"2019","author":"Bitossi","year":"2019","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ajo.2024.12.009_bib0013","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","article-title":"Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy","volume":"240","author":"Eurelings","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.009_bib0014","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ophtha.2019.11.024","article-title":"Drug retention rate and causes of discontinuation of adalimumab in uveitis: real-world data from the biotherapies in uveitis (Bio\u00davea) study group","volume":"127","author":"Lloren\u00e7","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.009_bib0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.009_bib0016","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjophthalmol-2021-319072","article-title":"Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study","volume":"106","author":"Sejournet","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0018","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2005.03.010","article-title":"The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study","volume":"183","author":"Panagiotakos","year":"2005","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.009_bib0019","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"Tilg","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.009_bib0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/rheumatology\/ket433","article-title":"Body weight, gender and response to TNF-\u03b1 blockers in axial spondyloarthritis","volume":"53","author":"Gremese","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.009_bib0021","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13075-023-03187-4","article-title":"High BMI is associated with lower TNF-\u03b1 inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis","volume":"25","author":"de Wolff","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.009_bib0022","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.009_bib0023","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.009_bib0024","series-title":"StatPearls","article-title":"BMI Classification Percentile And Cut Off Points","author":"Weir","year":"2024"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0021-9150(99)00156-2","article-title":"Plasma levels of the soluble fraction of tumor necrosis factor receptors 1 and 2 are independent determinants of plasma cholesterol and LDL-cholesterol concentrations in healthy subjects","volume":"146","author":"Fern\u00e1ndez-Real","year":"1999","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0026","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02172087","article-title":"The metabolic effects of tumor necrosis factor and other cytokines","volume":"3","author":"Grunfeld","year":"1991","journal-title":"Biotherapy"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.009_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2024.12.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105369","article-title":"Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease","volume":"150","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.009_bib0029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40262-018-0676-z","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis","volume":"58","author":"Berends","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.009_bib0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0031","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jcph.1732","article-title":"Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection","volume":"61","author":"Eser","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.009_bib0032","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1093\/rheumatology\/keab304","article-title":"Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review","volume":"60","author":"Sherbini","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajo.2024.12.009_bib0033","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajo.2024.09.008","article-title":"Adalimumab Drug Monitoring and Treatment Adjustment to Drug Antibodies in Noninfectious Uveitis","volume":"268","author":"Pichi","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.009_bib0034","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/kev356","article-title":"Biologic efficacy optimization\u2013a step towards personalized medicine","volume":"55","author":"Kiely","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/annrheumdis-2013-204101","article-title":"Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects","volume":"74","author":"Krieckaert","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.009_bib0036","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.phrs.2008.02.006","article-title":"Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis","volume":"57","author":"Saraceno","year":"2008","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.009_bib0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","article-title":"Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications","volume":"105","author":"Carrascosa","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.009_bib0038","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13346-017-0418-z","article-title":"Preclinical development of an automated injection device for intradermal delivery of a cell-based therapy","volume":"7","author":"Leoni","year":"2017","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.009_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-074864","article-title":"Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry","volume":"14","author":"Vallejo-Yag\u00fce","year":"2024","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.009_bib0040","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s10067-017-3585-x","article-title":"Association of obesity with patient-reported outcomes in patients with axial spondyloarthritis: a cross-sectional study in an urban Asian population","volume":"36","author":"Lee","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.009_bib0041","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:03:44Z","timestamp":1764839024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424005671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"alternative-id":["S0002939424005671"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.009","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Body Mass Index is Associated with Lower Adalimumab Serum Levels and Higher Disease Activity in Noninfectious Uveitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}